TY - JOUR
T1 - Preparation and characterization of amoxapine- and naringin-loaded solid lipid nanoparticles
T2 - drug-release and molecular-docking studies
AU - Jat, Sandeep
AU - Bhatt, Manini
AU - Roychowdhury, Sanjana
AU - Dixit, Vaibhav A.
AU - Pawar, Sachin Dattram
AU - Kulhari, Hitesh
AU - Alexander, Amit
AU - Kumar, Pramod
N1 - Publisher Copyright:
© 2023 Future Medicine Ltd.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Aim: Amoxapine (AMX) has been reported to be metabolized by CYP3A4 and CYP2D6. Naringin (NG) has been reported to inhibit CYP enzymes. Therefore, the current work was designed to develop AMX solid lipid nanoparticles (AMX-SLNs) and NG-SLNs for better therapeutic performance. Materials & methods: AMX-SLNs and NG-SLNs were prepared and characterized. AMX and NG interactions with CYP450s were studied with molecular docking to rationalize the effectiveness of the combination. Results: AMX-SLNs and NG-SLNs showed nanometric size with a sustained in vitro drug-release profile. NG showed a higher predicted binding affinity for CYP3A4 and CYP2D6, suggesting the potential for inhibition. Conclusion: The developed formulations were thoroughly characterized along with molecular docking data indicating promising AMX and NG combinations that may show good therapeutic activity.
AB - Aim: Amoxapine (AMX) has been reported to be metabolized by CYP3A4 and CYP2D6. Naringin (NG) has been reported to inhibit CYP enzymes. Therefore, the current work was designed to develop AMX solid lipid nanoparticles (AMX-SLNs) and NG-SLNs for better therapeutic performance. Materials & methods: AMX-SLNs and NG-SLNs were prepared and characterized. AMX and NG interactions with CYP450s were studied with molecular docking to rationalize the effectiveness of the combination. Results: AMX-SLNs and NG-SLNs showed nanometric size with a sustained in vitro drug-release profile. NG showed a higher predicted binding affinity for CYP3A4 and CYP2D6, suggesting the potential for inhibition. Conclusion: The developed formulations were thoroughly characterized along with molecular docking data indicating promising AMX and NG combinations that may show good therapeutic activity.
UR - https://www.scopus.com/pages/publications/85151168425
UR - https://www.scopus.com/inward/citedby.url?scp=85151168425&partnerID=8YFLogxK
U2 - 10.2217/nnm-2022-0167
DO - 10.2217/nnm-2022-0167
M3 - Article
C2 - 36786368
AN - SCOPUS:85151168425
SN - 1743-5889
VL - 17
SP - 2133
EP - 2144
JO - Nanomedicine
JF - Nanomedicine
IS - 28
ER -